News | December 12, 2024
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
The acquisition will strengthen the overall company’s position as leading global CRO services partner
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
He holds a Master’s in Management from the National University of Singapore
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
The Notes shall not be offered or sold in India
Subscribe To Our Newsletter & Stay Updated
